International Linked Clinical Trials (iLCT)
21 results.
LONDON (April 3, 2024) — Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may…
LONDON (Feb. 23, 2024) — Cure Parkinson’s and Van Andel Institute are delighted to announce funding for a Phase 2 clinical trial…
Copenhagen, Denmark (August 28, 2023) — A one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide has reported positive early results, which indicate…
Grand Rapids, Mich. (March 13, 2023) — Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce that their co-funding agreement, which supports…
London, United Kingdom (Jan. 10, 2023) — Following promising results reported at Phase 2 in 2020, a large-scale Phase 3 clinical trial of ambroxol,…
This release has been republished from Cure Parkinson’s. Researchers from Cedars Sinai Hospital, Los Angeles, have presented their initial top line results of
As 2021 comes to a close, so too does Van Andel Institute’s celebration of our 25th anniversary. The Institute’s story began with a vision: to…
Drug repurposing program seeks to find treatments that slow or stop Parkinson’s progression and serve as a roadmap for similar initiatives in other diseases Could…